Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) jumped 5.05% in pre-market trading on Thursday, following the release of positive Phase 2 data for its lead drug candidate REC-994 in treating cerebral cavernous malformations (CCM).
The company reported that in the Phase 2 SYCAMORE study, REC-994 met the primary endpoint of safety and tolerability, with no treatment-related discontinuations or Grade 3 adverse events. More importantly, the 400mg dose showed promising trends in reducing total lesion volume and improving functional outcomes as measured by the modified Rankin Scale (mRS). These positive signals were observed in both the overall study population and the subset of patients with brainstem lesions, representing a high unmet medical need.
Based on these encouraging results, Recursion plans to submit the data for publication in a peer-reviewed journal and engage in regulatory discussions on the next development steps for REC-994. The company also has an ongoing long-term extension study to gather additional data on REC-994's efficacy and safety profile.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。